Ventolin (albuterol)
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
130
Go to page
1
2
3
4
5
6
June 20, 2025
COMPIS: Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment
(clinicaltrials.gov)
- P=N/A | N=18 | Completed | Sponsor: Vastra Gotaland Region | Enrolling by invitation ➔ Completed | Trial completion date: Dec 2025 ➔ Mar 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2025
Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Musculoskeletal Diseases • Myositis
June 17, 2025
MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
(clinicaltrials.gov)
- P2 | N=118 | Completed | Sponsor: AstraZeneca | Trial completion date: Oct 2025 ➔ Jun 2025 | Trial primary completion date: Oct 2025 ➔ Jun 2025 | Recruiting ➔ Completed
Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
February 24, 2025
Assessment of a Valved Holding Chamber for Delivering Inhaled Medication Through a Tracheostomy Tube in a Tidal Breathing Model
(ATS 2025)
- " Albuterol (Ventolin™, 2-actuations) was delivered to the model via 2 different valved holding chambers (VHC, AEROTRACH PLUS® Anti-Static VHC and PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber) via 4.5mm or 8.0mm TTs... The choice of a metered-dose inhaler / VHC delivery system can significantly influence treatment efficacy. This study demonstrated that the AEROTRACH PLUS® Anti-Static VHC provided superior delivery of albuterol compared to the PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber (p<0.001). Optimizing lung deposition with the AEROTRACH PLUS® spacer may lead to faster symptom relief and potentially reduce the required number of actuations and cost of treatment."
Pediatrics • Pulmonary Disease • Respiratory Diseases
April 24, 2025
Patients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalers
(GOV.UK)
- "The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding patients with asthma of the importance of using their preventer (anti-inflammatory) inhaler regularly as prescribed, and to avoid relying on their blue inhaler alone. This is because without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks. This reminder follows updates to product information and the National Institute for Health and Care Excellence (NICE) guidance for short-acting beta 2 agonists (SABAs), including salbutamol and terbutaline, which are used to relieve sudden asthma symptoms such as chest tightness, wheezing, coughing and breathlessness."
NICE • Asthma
April 11, 2025
Role of Salbutamol in the Management of Transient Tachypnea of the New Born
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Khyber Teaching Hospital
New P1 trial
April 09, 2025
A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children
(clinicaltrials.gov)
- P4 | N=60 | Completed | Sponsor: Children's Hospital and Institute of Child Health, Multan
New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
February 19, 2025
MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
(clinicaltrials.gov)
- P2 | N=102 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
February 05, 2025
Evaluation of a cardboard-based spacer for enhancing aerosol delivery from pressurized metered dose inhalers.
(PubMed, J Asthma)
- "The in-vitro part evaluated salbutamol's aerodynamic particle size distribution (APSD) after 0, 20, 50, 120, and 200 uses of Ventolin pressurized metered dose inhaler (pMDI) when connected to MDI Plus using an Andersen cascade impactor at an inhalation flow of 28.3 L/min...The amount deposited on the MDI and the hands of the patients after multiple storage in the MDI Plus box and uses was insignificant and within the allowed limits. The MDI Plus simultaneously can act as an pMDI packaging box and spacer, serving as a practical, affordable, and accessible alternative to traditionally commercially available plastic spacers, particularly in resource-limited settings."
Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
November 19, 2024
Correct use of inhalers for asthma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
November 19, 2024
Drugs for asthma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
November 19, 2024
Comparison chart: Some inhaled drugs for treatment of asthma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
November 08, 2024
Pay to puff green: can NHS incentives change the prescribing practices?
(BTS WM 2024)
- "Comparator C2, involving salbutamol MDI swaps (mainly Ventolin to Salamol), showed significant improvement, with 8.11 new inhalers prescribed per 1,000 patients...When the inhaler swap did not necessitate introducing a new device and patient education (C2), the incentive was more effective. Despite the equal availability of the incentive, its uptake varied across England, potentially due to differences in guidelines and formularies ( figure 1 )."
Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases
November 05, 2024
Usability testing of a 3D-printed assistive device adaptor for a pressurized metered-dose inhaler
(APSR 2024)
- "Gripping force(s) required to depress the canister has significantly reduced by 73.5% (3.39kgfÀ0.90kgf) and 69.6% (2.73kgfÀ0.83kgf) for Ventolin and Atrovent respectively using Newton meter... 3D printed puff adaptors were effective in aiding patients with hand deficits in administering puffs."
Chronic Obstructive Pulmonary Disease • Immunology • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology
October 30, 2024
Comparison of 3% Hypertonic Saline and Salbutamol in Children With Bronchiolitis
(clinicaltrials.gov)
- P=N/A | N=100 | Not yet recruiting | Sponsor: University of Health Sciences Lahore
New trial • Pulmonary Disease • Respiratory Diseases
October 16, 2024
MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
(clinicaltrials.gov)
- P2 | N=102 | Not yet recruiting | Sponsor: AstraZeneca
New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
August 01, 2024
VALUE OF CHEST PHYSIOTHERAPY WITH CONTINUOUS POSITIVE AIRWAY PRESSURE IN 5-YEAR-OLD CHILDREN: EFFECTS ON ATELECTASIS IN AMBULATORY HOSPITAL CARE
(CHEST 2024)
- "After one month of hospitalization in intensive care, she finally left the hospital with an inhaled treatment (Axotide, Ventolin) but remained short of breath and tired... A respiratory physiotherapy adapted to continuous positive airway pressure can significantly reduce atelectasis firmly established for many months in a young child."
Clinical • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases
September 20, 2024
PRISM: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
(clinicaltrials.gov)
- P4 | N=100 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed
Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
June 01, 2024
Inhalation through two mini-spacer-like inhaler technique training devices: An in-vitro aerosol delivery comparative study
(ERS 2024)
- " 30 and 90 L/min inhalation flow rates over 2 and 5 sec were used to compare aerosol delivery of salbutamol from Ventolin Evohaler connected to FT and FTCR... The FT and FTCR delivered comparable salbutamol doses and fine particles (≤5 µm) under optimal and suboptimal inhalation through pMDI. The FTCR was privileged with lower throat deposition. Ultimately, these devices are intended to improve and maintain patients' correct pMDI use."
Preclinical • Respiratory Diseases
June 01, 2024
Does Use Of A Heat and Moisture Exchanger Affect pMDI Delivery to a Simulated Patient on Mechanical Ventilation
(ERS 2024)
- "5 actuations of Ventolin pMDI were delivered through 3 different delivery devices and a built-in port adapter in the circuit, followed by 6 complete breathing cycles... This study has shown that use of a bypass-type HME can allow delivery of medication to the patient. It also demonstrates that use of AeroChamber* VENT HC spacer could potentially reduce the carbon footprint by up to 4-fold compared to the alternative options. By maximizing the amount of each puff reaching the lungs the patient is likely to get relief sooner and reduce the number of puffs needed."
Clinical • Critical care • Respiratory Diseases
August 27, 2024
Drugs for COPD.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation
February 20, 2024
Projected Savings on Inhalers Purchased Via Mark Cuban Cost Plus Drug Company (MCCPDC) Versus Medicare Part-D
(ATS 2024)
- "Top Pulmonology inhalers studied were Albuterol Sulfate (Ventolin), Albuterol Sulfate (Proair), Albuterol sulfate (Proventil), Albuterol Sulfate HFA, Fluticasone Salmeterol (Advair Diskus) and Fluticasone Salmeterol (Advair HFA). Purchasing prescription drugs through MCCPDC showed substantial potential cost-savings for pulmonology directed rugs. MCCPDC could be a reasonable financial alternative for Medicare Part D spending on pulmonology drugs to reduce the financial burden of healthcare related costs."
Medicare • Reimbursement • US reimbursement • Alpha-1 Antitrypsin Deficiency • Chronic Obstructive Pulmonary Disease • Critical care • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
February 20, 2024
Performance of a Portable Spacer Compared to the Metered Dose Inhaler Alone and a Commonly Recommended Spacer
(ATS 2024)
- "5 actuations of Ventolin® or Atrovent® were delivered at 30s intervals to the device on test and the active pharmaceutical ingredient recovered from the CI was assayed by HPLC... These in vitro data provide guidance to the clinician that the new AeroChamber2go™ spacer provides only slightly lower fine particle dose (FPD) performance than the full-size standard spacer and similar FPD to that of the pMDI alone. Given the known real life coordination challenges using a pMDI alone, which may be even worse in a rescue situation, the portable spacer provides a more convenient alternative for those patients who currently do not use a spacer 'On the Go'."
Alpha-1 Antitrypsin Deficiency • Asthma • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
March 11, 2024
Airsupra: An inhaled albuterol/budesonide combination for asthma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
March 05, 2024
Warren rebukes GSK for alleged 'money grab' after company pulled popular asthma med
(Fierce Pharma)
- "After removing Flovent HFA from the market, GSK and its partner substituted an authorized generic version with a lower list price—currently around $310—compared to the branded product’s $340...The spokesperson explained that GSK elected to launch authorized generics for Flovent HFA and its sister product Flovent Diskus to help maintain patient access to the drug, potentially at a lower cost...GSK in December removed four patents related to its inhaler products Advair, Annuity, Flovent and Ventolin from the FDA’s Orange Book following the U.S. Federal Trade Commission’s (FTC’s) recent crackdown on 'improper' listings."
Discontinued • Patent • Pricing • Asthma
February 20, 2024
Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)
(clinicaltrials.gov)
- P=N/A | N=60 | Recruiting | Sponsor: Hat Yai Medical Education Center | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 25
Of
130
Go to page
1
2
3
4
5
6